Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
06:20pm, Thursday, 22'nd Feb 2024
Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago.
Here's Why You Should Retain Insulet (PODD) Stock for Now
09:30am, Friday, 16'th Feb 2024
The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
10:55am, Thursday, 08'th Feb 2024
Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 05'th Feb 2024
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Insulet (PODD) Gains From Product Innovation, Global Expansion
11:31am, Thursday, 01'st Feb 2024
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
5 top healthcare stocks for earnings growth in 2024
07:09am, Thursday, 25'th Jan 2024
Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.
Here's Why Insulet (PODD) is a Strong Growth Stock
10:46am, Monday, 22'nd Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
06:00am, Thursday, 11'th Jan 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
09:13am, Tuesday, 09'th Jan 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
11:18am, Friday, 05'th Jan 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
02:17pm, Friday, 29'th Dec 2023
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here are the 20 worst-performing stocks among the S&P 500 in 2023
11:18am, Friday, 29'th Dec 2023
The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
02:17pm, Thursday, 28'th Dec 2023
Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.
3 Medical-Device Stocks Could Click in 2024
02:30pm, Tuesday, 26'th Dec 2023
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
How to Find the Best Top-Ranked Stocks to Buy in 2024
05:17pm, Tuesday, 19'th Dec 2023
Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.
